RETA · Reata Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.75M | $195.0K | - | $540.0K | $762.0K | $914.0K | - | $7.39M | $2.22M | $944.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $57.12M | $55.48M | - | $43.48M | $39.33M | $39.80M | - | $39.43M | $40.07M | $34.88M |
| SG&A | $25.14M | $54.88M | - | $27.27M | $25.14M | $24.84M | - | $25.74M | $22.00M | $20.70M |
| Total Operating Expenses | $114.95M | $110.65M | - | $71.03M | $64.75M | $64.95M | - | $65.49M | $62.35M | $55.86M |
| D&A | $293.0K | $288.0K | - | $272.0K | $273.0K | $308.0K | - | $320.0K | $287.0K | $274.0K |
| Operating Income | $193.00M | ($116.12M) | - | ($79.00M) | ($73.56M) | ($73.81M) | - | ($71.85M) | ($73.35M) | ($67.47M) |
| Interest Expense | $1.31M | - | - | $0 | - | $0 | - | $1.83M | $1.77M | $1.71M |
| Income Tax | $0 | $0 | - | $0 | ($1.0K) | $31.0K | - | $0 | ($653.0K) | ($15.0K) |
| Net Income | $193.00M | ($116.12M) | - | ($79.00M) | ($73.56M) | ($73.84M) | - | ($71.85M) | ($72.70M) | ($67.45M) |
| EPS - Basic | $5.12 | ($2.03) | - | ($2.16) | ($2.02) | - | - | - | - | ($1.86) |
| EPS - Diluted | $4.65 | ($3.14) | - | ($2.16) | ($2.00) | - | - | - | - | ($1.86) |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.84M | $84.94M | $42.31M | $31.92M | $147.15M | $531.98M | $590.26M | $713.21M | $755.71M | $777.62M |
| Accounts Receivable | $0 | - | - | - | - | - | - | - | - | - |
| Inventory | $0 | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $19.86M | $14.45M | $18.71M | $7.52M | $7.75M | $9.02M | $13.51M | $1.74M | $8.41M | $8.26M |
| Current Assets | $401.85M | $332.54M | $397.77M | $445.10M | $491.21M | $537.34M | $596.48M | $721.66M | $767.68M | $805.52M |
| Total Assets | $502.59M | $453.58M | $514.49M | $583.64M | $631.55M | $679.87M | $735.02M | $731.85M | $777.61M | $815.08M |
| Current Liabilities | $125.09M | $54.60M | $58.96M | $50.71M | $46.33M | $43.62M | $53.99M | $121.28M | $121.10M | $114.36M |
| Long-term Debt | $73.13M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $87.29M | ($130.67M) | ($65.69M) | $4.52M | $68.64M | $127.78M | $185.99M | $255.98M | $313.83M | $369.33M |
| Retained Earnings | ($1.49B) | ($1.68B) | ($1.57B) | ($1.48B) | ($1.40B) | ($1.33B) | ($1.26B) | ($1.17B) | ($1.10B) | ($1.03B) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($81.45M) | - | - | - | ($58.19M) | - | - | - | ($45.01M) |
| Investing Cash Flow | - | $111.00M | - | - | - | ($288.0K) | - | - | - | ($193.0K) |
| Financing Cash Flow | - | $13.08M | - | - | - | $194.0K | - | - | - | $4.68M |
| CapEx | - | $141.0K | - | - | - | $288.0K | - | - | - | $193.0K |
| Free Cash Flow | - | ($81.59M) | - | - | - | ($58.47M) | - | - | - | ($45.20M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 848.5% | -59547.2% | - | -14630.0% | -9653.0% | -8075.6% | - | -972.1% | -3302.7% | -7147.2% |
| EBITDA margin | 849.8% | -59399.5% | - | -14579.6% | -9617.2% | -8041.9% | - | -967.7% | -3289.8% | -7118.2% |
| Net margin | 848.5% | -59547.2% | - | -14630.0% | -9652.9% | -8079.0% | - | -972.1% | -3273.3% | -7145.7% |
| Free cash flow margin | - | -41841.0% | - | - | - | -6397.5% | - | - | - | -4788.6% |
| FCF / Net income | - | 0.70 | - | - | - | 0.79 | - | - | - | 0.67 |
| R&D / Revenue | 251.1% | 28449.7% | - | 8052.8% | 5161.5% | 4354.9% | - | 533.5% | 1804.0% | 3694.9% |
| SG&A / Revenue | 110.5% | 28146.2% | - | 5050.0% | 3299.6% | 2717.8% | - | 348.2% | 990.5% | 2193.2% |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 38.4% | -25.6% | - | -13.5% | -11.6% | -10.9% | - | -9.8% | -9.3% | -8.3% |
| Return on equity | 221.1% | 88.9% | - | -1749.4% | -107.2% | -57.8% | - | -28.1% | -23.2% | -18.3% |
| Return on invested capital | 120.3% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.21 | 6.09 | 6.75 | 8.78 | 10.60 | 12.32 | 11.05 | 5.95 | 6.34 | 7.04 |
| Quick ratio | 3.21 | 6.09 | 6.75 | 8.78 | 10.60 | 12.32 | 11.05 | 5.95 | 6.34 | 7.04 |
| Cash ratio | 0.39 | 1.56 | 0.72 | 0.63 | 3.18 | 12.20 | 10.93 | 5.88 | 6.24 | 6.80 |
| Leverage | ||||||||||
| Debt / Equity | 0.84 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.15 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | 0.38 | - | - | - | - | - | - | - | - | - |
| Interest coverage | 147.1x | - | - | - | - | - | - | -39.2x | -41.4x | -39.4x |
| Equity multiplier | 5.76 | -3.47 | -7.83 | 129.24 | 9.20 | 5.32 | 3.95 | 2.86 | 2.48 | 2.21 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.01 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 0d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2885.0% | -78.7% | - | -92.7% | -65.7% | -3.2% | - | 427.6% | -27.7% | -30.2% |
| Revenue CAGR (3y) | 94.9% | -47.6% | - | -59.7% | -54.0% | -51.0% | - | -16.2% | -33.6% | -69.2% |
| Revenue CAGR (5y) | 24.6% | -64.0% | - | -46.7% | -43.1% | -41.0% | - | -10.0% | -29.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -57.3% | - | -10.0% | -0.3% | -9.4% | - | -9.6% | -8.5% | 5.2% |
| Net income growth (YoY) | - | -57.3% | - | -10.0% | -1.2% | -9.5% | - | -9.8% | -7.6% | -37.8% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | -26.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -39.5% | - | - | - | -29.4% | - | - | - | -9.6% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 27.2% | - | - | -98.2% | -78.1% | -65.4% | -55.4% | 37.7% | 35.5% | 61.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$11.49M totalLicense And Service$8.04M · 70.0%
Service Other$3.45M · 30.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing REATA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.